Global Non Hodgkin Lymphoma (NHL) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Non Hodgkin Lymphoma (NHL) market size will reach US$ million by 2031.

Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver.

United States market for Non Hodgkin Lymphoma (NHL) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Non Hodgkin Lymphoma (NHL) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Non Hodgkin Lymphoma (NHL) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Non Hodgkin Lymphoma (NHL) players cover F. Hoffmann-La Roche, Johnson & Johnson, Merck, Bristol Myers Squibb, Celgene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Non Hodgkin Lymphoma (NHL) Industry Forecast” looks at past sales and reviews total world Non Hodgkin Lymphoma (NHL) sales in 2024, providing a comprehensive analysis by region and market sector of projected Non Hodgkin Lymphoma (NHL) sales for 2025 through 2031. With Non Hodgkin Lymphoma (NHL) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non Hodgkin Lymphoma (NHL) industry.

This Insight Report provides a comprehensive analysis of the global Non Hodgkin Lymphoma (NHL) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non Hodgkin Lymphoma (NHL) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non Hodgkin Lymphoma (NHL) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non Hodgkin Lymphoma (NHL) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non Hodgkin Lymphoma (NHL).

This report presents a comprehensive overview, market shares, and growth opportunities of Non Hodgkin Lymphoma (NHL) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Standard
Exellent

Segmentation by Application:
Hosptial
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
F. Hoffmann-La Roche
Johnson & Johnson
Merck
Bristol Myers Squibb
Celgene
Eli Lilly
GlaxoSmithKline
Bayer

Please note: The report will take approximately 2 business days to prepare and deliver. Show more